about
Targeting BRAF in thyroid cancerSelective use of sorafenib in the treatment of thyroid cancerTERT promoter mutations in thyroid cancerMolecular Targeted Therapies of Aggressive Thyroid CancerUniverses collide: combining immunotherapy with targeted therapy for cancerTime to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaOptimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directionsUltrasonography of various thyroid diseases in children and adolescents: a pictorial essayCurrent status and future perspectives in differentiated thyroid cancerHighly prevalent TERT promoter mutations in aggressive thyroid cancers.The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?Prognostic value of the BRAF V600E mutation in papillary thyroid carcinomaBRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrenceDiagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trialEtiopathogenesis of Differentiated Thyroid CarcinomasTall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biologyAssociation of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancerProtein kinase A and B-Raf mediate extracellular signal-regulated kinase activation by thyrotropinOncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumorsLenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerA multiplex human syndrome implicates a key role for intestinal cell kinase in development of central nervous, skeletal, and endocrine systems.Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland China.Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.Survivin delta Ex3 overexpression in thyroid malignanciesOncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.Association between BRAFV600E mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma.Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours.A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinomaTERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.Personalized medicine: the future is not what it used to be.Thyroid cancer: current molecular perspectives.Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma.
P2860
Q24653496-E2BEC7C1-672D-4873-8539-B40729C5564DQ26752891-5CCFE072-7873-4D2E-9602-01BBDA1F5573Q26770808-631FE131-A6B1-481D-A3C5-1CA4D3A45E47Q26774734-52473C94-DF97-4E25-98D0-C8FCE34E870BQ26825316-2D281B07-A955-4F9F-B033-AE3061266DEDQ26853261-671F2794-D33C-41CB-924F-547B2FDE9ED4Q26863326-15302514-DDA5-4666-B380-AF5FEC5BD052Q26866176-CD7B66D8-0E75-4A97-93BB-AD2BE0F4B51CQ27024484-8575F2E2-2B3D-4A82-ADCA-B945A9077AF9Q27852353-2DE60233-33DD-41CD-B670-946130324195Q27852737-6A720401-F45A-44FC-9D00-11646A7BFD95Q27852780-235C3FED-1473-4136-9E93-34569BECB679Q27853042-81987504-A2F0-4FCD-853F-06E1B232D318Q27853057-3623B556-078B-4D8B-9B51-ABFFD8FD5797Q27853396-813FB3D8-F8EA-40FE-922A-8151EBAA0A90Q28071277-C388682C-AE2D-426B-943E-9A92685BC129Q28078437-1E3867BE-D762-456C-B440-A3F6CA87F787Q28253304-4E424D0F-09B2-438F-9938-ABB72930B24DQ28569443-D69ABF97-F043-4A66-ABA0-6625373F1BE0Q28756117-E4B2D677-7392-485A-96D1-23FA03DFF505Q30243995-054D28B3-7A77-4453-B19E-D17C7E673B1DQ30317867-C66178C6-84B5-4C4A-BDE3-131BCBDF906EQ30367068-A38A60AB-D754-419B-9073-E3D36EBAE873Q30374649-98EBD48A-FE4D-4ACD-B385-6D69C759895FQ30418749-D9A739CC-65F9-4EA7-A1B2-55162925E023Q30458424-3551ABF0-F997-41C0-8970-F41F8C21DEABQ30769508-2B490537-E7FF-438B-B074-49122142D5B7Q31114420-C56A7C48-7107-4FB5-A331-61FBA3D942ADQ31166524-EACA8B0D-3046-4269-A13B-0BF6D7F690C1Q33558907-E4BB8782-96FF-49D4-9FCD-2572C60339B4Q33574315-437DEC7F-910C-4FDD-A990-19AB515C3E8CQ33590611-50F6C9B6-6D6F-4569-B4E6-DE2D71D97AB1Q33597740-59AF208D-E144-4FED-A437-AFA1E45B2F09Q33629836-4B1BA0FE-491F-4439-BB88-53B79345A76FQ33630865-207809D3-BCD2-4EB0-9F94-E8CBE941DE6FQ33656624-7A4F4364-6A2D-40F4-99F8-8E0D574C31DFQ33682388-EE50683C-32E5-4C74-8736-2139A69DD46FQ33750281-6F912150-D502-4500-92B9-DADF13C28AA4Q33760910-C8907654-B24E-466D-AEF0-18E4B1E060D7Q33771043-7AF5231D-67CC-4C22-93C6-E50A14D7C408
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
BRAF mutation in thyroid cancer.
@ast
BRAF mutation in thyroid cancer.
@en
type
label
BRAF mutation in thyroid cancer.
@ast
BRAF mutation in thyroid cancer.
@en
prefLabel
BRAF mutation in thyroid cancer.
@ast
BRAF mutation in thyroid cancer.
@en
P356
P1476
BRAF mutation in thyroid cancer.
@en
P2093
P304
P356
10.1677/ERC.1.0978
P577
2005-06-01T00:00:00Z